Experts has a new look! Let us know what you think of the updates.

Provide feedback

Scholarly Works

American Society of Clinical Oncology Technology...

Journal article

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004

Abstract

Purpose To update the 2003 American Society of Clinical Oncology technology assessment on adjuvant use of aromatase inhibitors. Recommendations Based on results from multiple large randomized trials, adjuvant therapy for postmenopausal women with hormone receptor–positive breast cancer should include an aromatase inhibitor in order to lower the risk of tumor recurrence. Neither the optimal timing nor duration of aromatase inhibitor therapy is …

Authors

Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J

Journal

Journal of Clinical Oncology, Vol. 23, No. 3, pp. 619–629

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

January 20, 2005

DOI

10.1200/jco.2005.09.121

ISSN

0732-183X

Associated Experts

Timothy Whelan

Professor, Faculty of Health Sciences

Labels

Medical Subject Headings (MeSH)

Aged Aromatase Inhibitors Biomarkers, Tumor Breast Neoplasms Chemotherapy, Adjuvant Female Humans Middle Aged Neoplasm Recurrence, Local Postmenopause Prognosis Randomized Controlled Trials as Topic Receptors, Estrogen Receptors, Progesterone Risk Factors

Fields of Research (FoR)

3211 Oncology and carcinogenesis

View published work (Non-McMaster Users)

View published work (McMaster Users)